Compare ITRG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ITRG | TECX |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 60 |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.1M | 554.1M |
| IPO Year | 2017 | N/A |
| Metric | ITRG | TECX |
|---|---|---|
| Price | $2.47 | $30.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.13 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 1.9M | 202.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $67.34 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $14.39 |
| 52 Week High | $4.87 | $35.99 |
| Indicator | ITRG | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 55.67 |
| Support Level | N/A | $27.39 |
| Resistance Level | $3.29 | $31.17 |
| Average True Range (ATR) | 0.13 | 1.94 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 10.24 | 60.38 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.